Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GEN amended an ongoing open-label, dose-escalation Phase III trial in 92 patients with mycosis fungoides (MF)
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury